The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.

Researchers described a new skin disease in a male patient with erythroderma, causing 80 percent of his skin to be covered with red, exfoliating skin lesions that itched and burned. After undergoing ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no ...